pSivida (PSDV) Announces Earnings Results, Beats Estimates By $0.02 EPS
pSivida (NASDAQ:PSDV) announced its earnings results on Wednesday. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02, Yahoo Finance reports. The company had revenue of $0.93 million during the quarter, compared to analysts’ expectations of $0.48 million. pSivida had a negative return on equity of 139.56% and a negative net margin of 226.31%.
pSivida (PSDV) traded down $0.01 during trading hours on Thursday, hitting $1.05. The stock had a trading volume of 270,450 shares, compared to its average volume of 419,195. The firm has a market capitalization of $49.49, a price-to-earnings ratio of -2.37 and a beta of 1.26. pSivida has a 1-year low of $1.00 and a 1-year high of $2.45.
Several brokerages have recently issued reports on PSDV. HC Wainwright set a $5.00 price objective on pSivida and gave the company a “buy” rating in a research note on Thursday. B. Riley set a $5.00 price objective on pSivida and gave the company a “buy” rating in a research note on Monday, December 4th. Laidlaw began coverage on pSivida in a research note on Wednesday, November 8th. They issued a “buy” rating and a $5.00 price objective for the company. Northland Securities reiterated a “buy” rating and issued a $10.00 price objective on shares of pSivida in a research note on Monday, December 11th. Finally, ValuEngine cut pSivida from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $7.57.
pSivida Company Profile
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.
Receive News & Ratings for pSivida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida and related companies with MarketBeat.com's FREE daily email newsletter.